source
- Iambic Therapeutics eyes IPO as it pushes HER2 inhibitor IAM1363 into early trialsIambic Therapeutics, a San Diego AI‑driven biotech, said it is preparing for an initial public offering after securing several large‑scale partnerships with major pharmaceutical companies. In its…
- FDA issues third warning letter to Empower Pharmacy over GLP-1 weight-loss treatmentsThe U.S. Food and Drug Administration sent a formal warning letter to Empower Pharmacy, a compounder based in Houston, concerning its GLP-1 weight-loss products. The notice marks the company's thi…